Professional Documents
Culture Documents
Drugs
Drugs
Generic
Brand
Antihistamine
(1st gen)
Diphenhydramine
Benad
ryl
Antihistamine
(2nd gen)
Fexofenadine
Allegra
Onset/durati
on
Onset=15m
in to 1 hr
Duration=4
to 6 hours
12-24 hrs
Pharmacology/ot
hers
Dirty drug
Sedating effect
Dosing
(Adults/Children
25-50 mg every 6 to
8 hours
Most interaction
Antihistamine
(2nd gen)
Antihistamine
(2nd gen)
Cetirizine
Loratadine
Reacti
ne
Clariti
n
Aerius
Onset: 20
minutes
Duration: 24
hrs
12-24 hrs
Antihistamine
(2nd gen)
Desoloratadine
Decongestant
(topical)
Xylometazoline
hydrochloride
Onset:
within 24
hours
Duration: 24
hrs
Up to 12
hours
Decongestant
(topical)
Oxymetazoline
hydrochloride
Up to 12
hours
Decongestant
(topical)
Phenylephrine
Hydrochloride
Up to 4
hours
Decongestant
(Topical)
Phenylephrine
Hydrochloride
Up to 4
hours
Decongestant
(Systemic)
Pseudoephedrine
(or Ephedrine)
Hair growth
Minoxidil
Hair growth
Finasteride
Sudafe
d
3 to 8 hours
Growth
within 6 to 9
month
10% sedating
effect
5-10mg
2.5-5mg(2-6years)
Cardiac effects
10mg
5 mg (2-5 years)
5mg
See table for children
Alpha-1
adrenoceptor
agonist
Alpha-1
adrenoceptor
agonist
Alpha-1
adrenoceptor
agonist
Alpha-1
adrenoceptor
agonist
Alpha 1
adrenoreceptor
agonist and NE
stimulate/block
reuptake
Increase hair
follicles and
duration of
anagen phase
Decreases 5
Risk of rhinitis
medicamentosa
Increase in BP,
restlessness
alpha reductase,
decrease
dihydrotesterone
Antibiotic
Mupirocin
Antibiotic
Calcinuerin
Inhibitor
Fusidic Acid
Cyclosporine
Vitamin D
analogues
Calcipotriol
100gs per
week
Immunosuppres
sion
Methotrexate
SC or orally
per week
Immunosupressi
on
Apremilast
Biological
Adalimuab
BID with 5
day
escalating
titration
Twice a
month SC
Starter
week 0,2,6,
and
maintenanc
e every 8
weeks, IV
Twice
weekly for 3
month,
weekly
injection
afterwards
SC
Starter
week 0 and
4, 3 month
Infliximab
Etanercept
Ustekinumab
2 to 3 times
a day for 7
to 10 days
BID up to 1
years
Decreases NFAT
dephosphorylatio
n, reduces
immune
response
Promotes
keritinizaiton
differentiaton
and decreases
proliferation
Inhibits
diphenylfolate
reductase which
in turn affects
immune
response
Inhibits PL4 to
increase cAMP
levels
Inhibit TNF
Inhibits TNF
Inhibit TNF
Inhibits IL-12/23
years
Category X
Secukinumab
SC
Week 0,
1,2,3, and
maintance
every
month
Inhibits IL-17A